Fiche du document
août 2023
- handle: 10670/1.kdurpy
- inserm-04517271
- doi: 10.1016/j.euo.2023.08.003
- PUBMED: 37640583
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.euo.2023.08.003
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37640583
Mots-clés
Erectile dysfuction Magnetic resonance–guided radiation therapy Penile bulb Prostate cancer Radiotherapy -bio]/CancerSujets proches
Radiation therapyCiter ce document
Jennifer Le Guevelou et al., « Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review », HALSHS : archive ouverte en Sciences de l’Homme et de la Société, ID : 10.1016/j.euo.2023.08.003
Métriques
Partage / Export
Résumé
Context: Erectile dysfunction represents a major side effect of prostate cancer (PCa) treatment, negatively impacting men's quality of life. While radiation therapy (RT) advances have enabled the mitigation of both genitourinary and gastrointestinal toxicities, no significant improvement has been showed in sexual quality of life over time.Objective: The primary aim of this review was to assess sexual structures' dose-volume parameters associated with the onset of erectile dysfunction.Evidence acquisition: We searched the PubMed database and ClinicalTrials.gov until January 4, 2023. Studies reporting the impact of the dose delivered to sexual structures on sexual function or the feasibility of innovative sexual structure-sparing approaches were deemed eligible.Evidence synthesis: Sexual-sparing strategies have involved four sexual organs. The mean penile bulb doses exceeding 20 Gy are predictive of erectile dysfunction in modern PCa RT trial. Maintaining a D100% of ≤36 Gy on the internal pudendal arteries showed preservation of erectile function in 88% of patients at 5 yr. Neurovascular bundle sparing appears feasible with magnetic resonance-guided radiation therapy, yet its clinical impact remains unanswered. Doses delivered to the testicles during PCa RT usually remain